PT  - JOURNAL ARTICLE
AU  - Andrea Salm
AU  - Sandhya R. Krishnan
AU  - Marta Collu
AU  - Ombeline Danton
AU  - Matthias Hamburger
AU  - Marco Leonti
AU  - Giovanna Almanza
AU  - Jürg Gertsch
TI  - Phylobioactive hotspots identified through multidimensional profiling of botanical drugs used to treat Chagas disease in Bolivia and Dioscorides’ De Materia Medica
AID  - 10.1101/862029
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 862029
4099  - http://biorxiv.org/content/early/2019/12/02/862029.short
4100  - http://biorxiv.org/content/early/2019/12/02/862029.full
AB  - Globally, more than six million people are infected with Trypanosoma cruzi, the causative protozoan parasite of the vector-borne Chagas disease (CD). In Bolivia, CD is hyperendemic and a major health problem among indigenous communities. Although botanical drugs are used widely among different ethnic groups in Bolivia, studies challenging the hypothesis that effective antitrypanosomal medicinal agents were identified empirically are lacking. We conducted a cross-sectional ethnopharmacological field study in Bolivia among different ethnic groups in the Chaco, Chiquitanía and Inter-Andean valleys. We compared botanical drugs used in Bolivia in the context of CD with botanical drugs from unrelated indications from the Mediterranean De Materia Medica (DMM) compiled by Dioscorides two thousand years ago. A total of 775 ethyl acetate plant extracts with and without ethnomedical indications for CD treatment were profiled against T. cruzi epimastigote and procyclic T. brucei proliferation, parasite release from T. cruzi trypomastigote infected cells, as well as for host cell cytotoxicity in vitro. Inhibition of parasite release was monitored using a flow cytometry-based celluar assay. At 25 µg/mL, less than 5% of all extracts exhibited selective toxicity for T. cruzi. We found no evidence that ethnomedicine-inspired bioprospecting significantly increased the probability of finding selective antichagasic botanical drugs. The ethnomedical data further indicate a discrepancy between local and scientific concepts about CD among the studied ethnic groups. Intriguingly, the phylobioactive anthraquinone hotspot identified in this study matched the antichagasic activity of Senna chloroclada, the taxon with the strongest consensus for treating CD among the Izoceño-Guaraní. Selected antitrypanosomal plant extracts from DMM were subjected to HPLC-based activity profiling and targeted isolation of active compounds yielding sesquiterpene lactones, naphtoquinones and anthraquinones. Because the anthraquinone emodin selectively and potently inhibited T. cruzi in host cell infection, we performed a preliminary structure-activity relationship analysis for the 9,10-anthracenedione scaffold, exploring the impact of differential hydroxylation. This study shows that the multidimensional phylobioactivity-guided identification of antichagasic natural products enables comparative bioprospecting and is suitable to challenge ethnopharmacological hypotheses.Author summary Chagas disease (CD) is a parasitic disease caused by the protozoan Trypanosoma cruzi. In Bolivia, CD is a major health problem among indigenous communities, which frequently use traditional medicine to treat the chronic symptoms of the disease related to cardiomyopathy. However, the ethnomedical context of the use of such remedies is largely unclear and it remains unknown whether the botanical drugs have any effect on parasitemia. In a field study among different ethnic groups in the Chaco, Chiquitanía and Inter-Andean valleys the authors collected ethnobotanical and ethnopharmacological information. Later, they profiled and compared the CD botanical drug extract library from Bolivia with a botanical drug extract library from the Mediterranean De Materia Medica with no association to CD. Using phylogenetic and biological information, they identified bioactive hotspots among different taxa and isolated antichagasic natural products. This led to a first structure-activity relationship study of the natural product class called anthraquinones. While there was no overall statistical difference between the libraries, it is noteworthy that the botanical drug derived from Senna chloroclada with the highest consensus among the Guaraní communities, also belonged to the anthraquinone cluster, potentially providing a molecular explanation for its use.